GHRP-2 placeholder product image

GHRP-2

Nazwy alternatywne
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
CAS
158861-67-7
Wzór cząsteczkowy
C45H55N9O6
Masa cząsteczkowa
818.00
Sekwencja aminokwasowa
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Rozmiar:
89 

Ten produkt jest przeznaczony wyłącznie do celów badawczych i laboratoryjnych (in vitro). Nie jest przeznaczony do zastosowań diagnostycznych, terapeutycznych, spożywczych, kosmetycznych, weterynaryjnych ani suplementacyjnych.

Zakupu mogą dokonywać wyłącznie osoby dorosłe. Kupujący potwierdza posiadanie odpowiedniej wiedzy i kwalifikacji do bezpiecznego obchodzenia się z chemikaliami badawczymi.

Opis produktu

What is GHRP-2?

GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂, belonging to the class of hormone secretagons growth (GHS). The compound was developed as part of a research program aimed at identifying molecules capable of stimulating the release of growth hormone (GH) from the pituitary gland through a growth hormone-releasing hormone (GHRH)-independent mechanism.

Structurally, GHRP-2 is characterized by the presence of D-amino acids (D-Ala, D-2-Nal, D-Phe), which make the molecule resistant to enzymatic degradation and extend the half-life compared to peptides composed only of L-amino acids. The molecular weight is approximately 818 Da and the molecular formula is C₄₅H₅₅N₉O₆. The presence of unnatural amino acids, such as D-2-naphthylalanine (D-2-Nal), is crucial for the high affinity for the growth hormone secretagon receptor.

GHRP-2 acts as an agonist of the GHS-R1a receptor (Growth Hormone Secretagogue Receptor type 1a), which is also a natural receptor for ghrelin - an endogenous peptide hormone produced mainly in the stomach. The binding of GHRP-2 to GHS-R1a in the pituitary somatotropes leads to cell depolarization, influx of calcium ions and secretion of growth hormone in a pulsatile manner imitating the physiological secretion pattern.

PMC
  • Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. PubMed
  • Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346-360. PubMed
  • Popovic V et al. Serum ghrelin levels in patients with growth hormone deficiency evaluated with growth hormone releasing hormone-growth hormone releasing peptide-2 test. J Clin Endocrinol Metab. 2004;89(11):5478-5483. PubMed
  • Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMC
  • Muccioli G et al. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris). 2000;61(1):27-31. PubMed
  • Vestergaard PF et al. Ghrelin and growth hormone secretagogues in health and disease. Pituitary. 2020;23(5):500-520. PubMed
  • Cordido F et al. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects. Metabolism. 1995;44(6):745-748. PubMed
  • Laferrère B et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. PubMed
  • Micic D et al. Growth hormone secretagogues: clinical experience and perspectives. Pediatr Endocrinol Rev. 2008;5 Suppl 2:786-795. PubMed
  • This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.